Axogen (FRA:LT3) Total Operating Expense: €161.2 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LT3 Axogen Inc FRA:LT3
64 GF Score
Price €33.02
GF Value €12.34
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Axogen Total Operating Expense?

Axogen FRA:LT3 -0.48% 64 Total Operating Expense is €161.2 Mil as of Mar. 2026. GuruFocus rates FRA:LT3 with a GF Score™ of 64/100 and a GF Value™ of €12.34 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Axogen's Total Operating Expense for the three months ended in Mar. 2026 was €42.4 Mil. Axogen's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €161.2 Mil.

Axogen Total Operating Expense Related Terms

Axogen Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Axogen's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axogen Total Operating Expense Chart

Axogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 114.91 130.76 131.44 138.73 149.62

Axogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.85 34.98 37.56 46.27 42.40
FRA:LT3
64GF Score
Axogen Inc FRA:LT3
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axogen Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €161.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €161.2 Mil mean?
Axogen (FRA:LT3) has a Total Operating Expense of €161.2 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Axogen and its competitors.
Is Axogen's Total Operating Expense too high?
Axogen's current Total Operating Expense is €161.2 Mil. Overall, Axogen has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Axogen's Total Operating Expense compare to TMDX and BFLY?
Axogen's Total Operating Expense of €161.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Axogen and its competitors. Axogen's current Total Operating Expense is €161.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axogen stock overvalued right now?
Based on GuruFocus' analysis, Axogen (FRA:LT3) is currently considered Significantly Overvalued. The stock's GF Value™ is €12.34, compared to a current price of €33.02 — trading 167.6% above its estimated fair value. The current Total Operating Expense is €161.2 Mil. Axogen's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Axogen (FRA:LT3), the current Total Operating Expense is €161.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axogen (FRA:LT3) Overvalued in 2026?

Based on GuruFocus' analysis, Axogen stock appears to be overvalued. The current stock price of €33.02 is trading 167.6% above its estimated GF Value™ of €12.34. GuruFocus considers Axogen to be Significantly Overvalued.

Key valuation signals for FRA:LT3:

  • Total Operating Expense: €161.2 Mil
  • GF Value™: €12.34 vs. price of €33.02 (167.6% above fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the FRA:LT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axogen Business Description

Other Exchanges AXGN:USA0HKD:UKLT3:Germany
Address 13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
64GF Score

Get the complete analysis for FRA:LT3

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.02
Price
€12.34
GF Value